SG Americas Securities LLC Sells 244,498 Shares of Qiagen (NYSE:QGEN)

SG Americas Securities LLC lessened its position in Qiagen (NYSE:QGEN) by 52.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,704 shares of the company’s stock after selling 244,498 shares during the period. SG Americas Securities LLC owned 0.10% of Qiagen worth $9,783,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in QGEN. Wellington Management Group LLP increased its stake in shares of Qiagen by 77.7% in the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after buying an additional 9,293,040 shares during the period. Barclays PLC raised its stake in shares of Qiagen by 170.6% during the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock valued at $84,259,000 after acquiring an additional 1,165,594 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Qiagen by 62.6% during the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after purchasing an additional 991,325 shares during the period. Point72 Asset Management L.P. grew its stake in shares of Qiagen by 148.8% in the second quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock worth $48,684,000 after purchasing an additional 708,533 shares during the last quarter. Finally, Point72 DIFC Ltd increased its holdings in Qiagen by 10,610.4% in the third quarter. Point72 DIFC Ltd now owns 649,693 shares of the company’s stock valued at $29,606,000 after purchasing an additional 643,627 shares during the period. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Trading Down 2.9 %

NYSE:QGEN opened at $45.86 on Friday. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.93. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $10.47 billion, a price-to-earnings ratio of 117.59, a PEG ratio of 3.51 and a beta of 0.37. The firm has a fifty day simple moving average of $44.43 and a two-hundred day simple moving average of $44.22.

Analyst Ratings Changes

Several brokerages have commented on QGEN. Morgan Stanley reaffirmed an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 price objective (up from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.50.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.